CarpX


MARKET OPPORTUNITY

 

CLINICAL

  • Carpal tunnel syndrome (CTS)
  • Most common cumulative trauma disorder and occupational injury

 

ADDRESSABLE MARKET

  • ~2 million patients and 350,000 surgeries annually1
  • Total: All CTS patients $1.5B
  • Immediate: Current Surgical Patients $750M

 

CURRENT DEVICE LIMITATIONS

  • Invasive
  • Require surgical OR procedure
  • Endoscopic procedures associated with higher complication rates
  • Remains an invasive surgical procedure
  

PAVMED SOLUTION

 

CARPX

  • Completely percutaneous device to treat CTS
  • Tissue dissecting balloon with integrated cutting and sensing elements

 

LESS INVASIVE

  • Truly percutaneous, no surgical incision or dissection
  • Reduces pain and accelerates return to full activity

 

MORE COST EFFECTIVE

  • Shifts procedures from OR to interventional suite/office
  • Shortens procedural times

 

FEWER COMPLICATIONS

  • Better nerve protection
  • Greater lateral dissection may decrease recurrence rates

 

EXPANDED MARKET

  • Benefits will lower threshold for intervention



This product is in the development phase and has yet to receive regulatory approval.